Inconsistent Reporting of Potential Conflicts of Interest

Vinay Prasad^{1

2}

Affiliations

¹ Division of Hematology Oncology, Knight Cancer Institute, Portland, Oregon.
² Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, Oregon.

Comment

Vinay Prasad. JAMA Intern Med. 2018.

. 2018 Oct 1;178(10):1424-1425.

doi: 10.1001/jamainternmed.2018.3695.

Vinay Prasad^{1

2}

¹ Division of Hematology Oncology, Knight Cancer Institute, Portland, Oregon.
² Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, Oregon.

No abstract available

Comment on

Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter.
Tao DL, Boothby A, McLouth J, Prasad V. Tao DL, et al. JAMA Intern Med. 2017 Mar 1;177(3):425-427. doi: 10.1001/jamainternmed.2016.8467. JAMA Intern Med. 2017. PMID: 28114456 No abstract available.
Limitations Concerning the Association of Physician Sex and Patient Outcomes.
Friedberg MW, Gellad WF, Prasad V. Friedberg MW, et al. JAMA Intern Med. 2017 Jul 1;177(7):1058. doi: 10.1001/jamainternmed.2017.2142. JAMA Intern Med. 2017. PMID: 28672361 No abstract available.
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V, Mailankody S. Prasad V, et al. JAMA Intern Med. 2017 Nov 1;177(11):1569-1575. doi: 10.1001/jamainternmed.2017.3601. JAMA Intern Med. 2017. PMID: 28892524 Free PMC article.
Assessing Pharmaceutical Research and Development Costs-Reply.
Prasad V, Mailankody S. Prasad V, et al. JAMA Intern Med. 2018 Apr 1;178(4):588-589. doi: 10.1001/jamainternmed.2017.8737. JAMA Intern Med. 2018. PMID: 29610885 No abstract available.
Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration.
Gerrity MS, Prasad V, Obley AJ. Gerrity MS, et al. JAMA Intern Med. 2018 Jun 1;178(6):743-744. doi: 10.1001/jamainternmed.2018.0869. JAMA Intern Med. 2018. PMID: 29710299 No abstract available.